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1. Introduction 
Over the last two decades, glycosidase inhibitors have been a 
key target for academic researchers, because of their role in a 
variety of ailments [1], such as: diabetes mellitus type II [2], 
cancer [3], hepatitis [4], HIV [5] and Gaucher disease [6]. One of 
the most studied classes of inhibitor are the polyhydroxylated 
pyrrolidines and piperidines [7]. Before the 90s [8] most 
glycosidase inhibitors studied were obtained from plants and 
micro-organisms, and three important examples are: 
deoxynojirimycin (DNJ), 2R,5R-dihydroxymethyl-3R,4R-
dihydroxypyrrolidine (DMDP) and 1,4-dideoxy-1,4-imino-d-
arabinitol (DAB) (Figure 1). These three molecules since the 90s
have been the prototypes for the synthesis of a wide range of 
potential glycosidase inhibitors [1]. For example, miglitol, an N-
alkyl derivative of DNJ used in the treatment of diabetes [2]. 
Curiously, Miglustat (N-butyl DNJ, Zavesca) is structurally 
similar to miglitol and is licensed for substrate reduction therapy 
in Gauchers disease. In the case of DAB, it shows strong 
inhibition of α-glucosidases, but its enantiomer, LAB is more 
potent and specific than DAB [9]. In the literature there exists an 
extensive variety of iminosugars with structures based on the 
pyrrolidine unit, which exhibit α-glucosidase activity. Several 
derivatives of DAB were synthetized and tested in different types 
of α-glucosidades [10]. Most of the structures were 
functionalized with alkyl [11], aryl [12], amide [13], amine [13], 
or alcohols [14] units in the 2,5-positions of the pyrrolidine ring. 
In 2012 Kato et al. [11a] described a new family of potent 
pyrrolidine α-glucosidase inhibitors; this family was basically a 
set of analogues of the LAB structure, having alkyl chains of 
different lengths in the 2 and 4 positions. The most promising α-
glucosidase inhibitor was the 1-C butyl derivative, which is one 
order of magnitude more active than LAB (Figure 1). On the 
contrary, the 2,4 dibutyl derivative didn´t show any inhibition, 
leading us to conclude that the hydroxyl group in the 4-postion is 
important for α-glucosidase inhibition.    
Recently we designed and synthesised a small library of 
pyrrolidine iminocyclitol inhibitors with a structural similarity to 
DAB. This library was specifically designed to gain a better 
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insight into the mechanism of inhibition of glycosidases by 
polyhydroxylated pyrrolidines. These compounds were assayed 
for baker’s yeast α-glucosidadse inhibition using acarbose as a 
reference and it was the non-benzylated diol 7’ which showed the 
highest inhibition (IC50 = 10.9 mM). It seems that the presence of 
a free NH group and free hydroxyl groups in the 3 and 4 
positions are important for favorable interaction with the enzyme 
active site. There were no substituents in the 2,5-position of the 
pyrrolidine ring in these compounds, but it appears quite obvious 
now that the presence of substituentes in these positions is 
important for inhibition [7]. Our results are similar to those 
obtained with the iminosugars reported by Bols [15] and Lundt 
[16] (Figure 1), although in their case the 3,4-hydroxy groups had 
a cis relative configuration.   
Figure 1. Examples of natural and synthetic iminosugars. 
In this publication we report on a study of another library of 1-
benzyl-3-hydroxypyrrolidine derivatives (1, 1’, 2, 2’, 3, 3’, 4, 4’) 
and 1-benzyl-3,4-dihydroxypyrrolidne derivatives (5, 5’, 6, 7), 
derived from D- and L-malic acid and D- and L-tartaric acid (Fig. 
2), respectively. It must be noted that a wide range of important 
pharmacologically active compounds contain the 3-
hydroxypirrolidine subunit, one example is Barnidipine, an 
antihypertensive agent [17]. In our study, the compounds were 
assayed for rat intestine α-glucosidase (EC 3.2.1.20) [18] 
inhibition, as well as the mechanism of inhibition and KI
determination. Acarbose and DNJ were used as references. 
Cytoxicity studies were also conducted for compounds 5, 5’ and 
7. Docking studies were realized with the human α-glucosidase 
(intestinal maltase-glucoamylase) and a homology model of rat 
glucosidase. We wanted to compare both the 
monohydroxypyrrolidine and dihydroxypyrrolidine series with 
pyrrolidines lacking an hydroxyl group. The structural diversity 
encountered in this library was for the purpose of probing the 
mechanism of inhibition of α-glycosidase, so that we can design 
and synthesize more potent, non-toxic α-glycosidase inhibitors. 
On the basis of our last publication we observed that O-
acetylated dihydroxypyrrolidines - despite showing good docking 
simulations [7a] - seem to suffer hydrolysis during the biological 
assays, and for this reason we decided to substitute the acetyl 
group for the more robust benzyl group. Besides this the 
possibility of the benzyl groups establishing significant non-
covalent π−π interactions with the active site residues was very 
likely, and worth investigating.  
2. Materials and Methods 
2.1. General Chemical 
All reagents were obtained from Aldrich, Fluka, Alfa Aesar or 
Acros. Solvents were dried using common laboratory methods. 
Compounds 5 and its respective enantiomer 5’ were synthesized 
using the precursors: (3S,4S)-N-benzyl-3,4-dihydroxy-2,5-
dioxopyrrolidine and (3R,4R)-N-benzyl-3,4-dihydroxy-2,5-
dioxopyrrolidine, respectively, both enantiomers had an 
enantiomeric purity of 99% ee. TLC was carried out on 
aluminium backed Kiselgel 60 F254 plates (Merck) and the plates 
were  
Figure 2. Library of 5-membered iminosugars synthetized and test. 
visualized either by UV light or with phosphomolybdic acid in 
ethanol. The 1H NMR and 13C NMR spectra were recorded on a 
Bruker Avance instrument (1H: 400 MHz and 13C: 100 MHz) 
using CDCl3 as solvent and the signal from residual CHCl3 as an 
internal standard (for the measurements made with the Bruker 
Avance instrument). Specific rotations were measured on a 
Perkin-Elmer 241 polarimeter. 
2.2. General Biological assays 
2.2.1 Enzymat ic assays with rat  α-glucosidase 
The enterocytes were isolated from Wistar rat small intestine 
according to Watford et al., 1979 [19a] with few modifications. 
Briefly, the α-glucosidase rich homogenates were obtained after 
mucus removal with calcium free Krebs-Henseilt buffer (in mM: 
120 NaCl, 2 KCl, 26 NaHCO3, 10 MgSO4, 1.18 KH2PO4, 11 
glucose, 5 EDTA; supplemented with 0.25% (p/v) BSA; at 37ºC 
during 20 min under mild stirring – 60 rpm) and detachment of 
mucosa epithelial cells using Krebs-Henseilt buffer (as 
previously described without EDTA and with 0.5 mM CaCl2, 
supplemented with 2.5% (p/v) BSA). The total protein 
  
concentration was determined using the Bradford dye-binding 
method [19b].  
The α-glucosidase activity was determined by monitoring the 
p-nitrophenol (p-NP) released from p-nitrophenyl-α-D-
glycopyranoside spectrophotometrically at 405 nm, over 60 min. 
The assay mixture had the following composition: 0.1M 
phosphate buffer (pH 6.7), 12 mM p-nitrophenyl-α-D-
glucopyranoside (the method was optimized giving KM and Vmax
values of 0.961 mM and 2.51x10-5 mmol p-NP.min-1.mg-1, 
respectively) and 30 μg/mL rat enterocyte α-glucosidase rich 
homogenates. The test compounds were dissolved in 2% DMSO 
in 0.1M phosphate buffer (pH 7) and solutions with concentration 
in the range of 0.01 x 10-3 and 92 mM were used. All 
experiments were performed in 5 replicates. The IC50 values were 
obtained from the inhibition curves. 
2.2.2 Toxici t y assays 
The toxicity of the compounds was measured using two 
methods. The first method described consists in the 
determination of the cell viability of the cellular line BRIN-BD 
11 from pancreatic beta cells. The second method was the 
evaluation of the half maximal lethal concentration (LC50) using 
Artemia salina.  
2.2.2. 1 Cy to toxi ci ty Assay 
BRIN BD-11 cells were cultured in 96 well micro plates 
(2x104 cells/well) in an incubator at 37ºC with 5% CO2 and 95% 
O2. The cells were exposed to the test compounds in the 
concentration range of 3 – 50 mM for 24 h. A negative control 
(without inhibitors) and a positive control (1% sodium dodecyl 
sulfate) tests were performed. Cell viability was determined 
using the cell counting kit-8 (CCK-8, Sigma-Aldrich) as 
established by the supplier.  
2.2.2. 2 Art emia sal ina l ethal  t oxi ci t y assay 
The percentage of dyed nauplii of Artemia salina, grown in 
the presence of variable concentrations of the inhibitor 
compounds, was measured to determine the LC50 values. The 
Artoxkit M was used. 
2 .2.3 Stat i st i cal  analysis 
Results are presented as mean ± sd for a given number of 
observations. Statistical analyses were done using one-way 
ANOVA for enzymatic activity. In the case of the toxicological 
results Paired-samples t-Test was used for comparison with 
samples showing negative control.    
2.3. Molecular Modeling 
2.3.1.  Molecular docking calculations 
Molecular docking calculations of the synthesized compounds 
with human and a homology model of rat α-glucosidase were 
performed with GOLD 5.1.0 (Genetic Optimization Ligand 
Docking) [20] software using the Goldscore scoring function. 
This software uses an evolutionary genetic algorithm to optimize 
the docked conformation of the flexible inhibitor within the 
enzyme. The docking calculations were performed using the 
homology model described in the next section for the rat α-
glucosidase and the available human α-glucosidase 
crystallographic structure. The experimental x-ray structure was 
obtained from the RCSB Protein Data Bank (PDB ID 3L4U, 
resolution 1.9 Å). The preparation of the human α-glucosidase 
structure involved the removal of the original crystallographic 
ligand (kotalanol) as well as the crystallographic waters. The 
protonation and tautomeric states of Asp, Glu, Arg, Lys, and His 
were adjusted to match a pH of 7 using the Protonate 3D 
algorithm within the Molecular Operating Environment (MOE) 
2012.10 program (www.chemcomp.com). These enzyme 
structures and the proposed docking protocol were previously 
validated by re-docking the co-crystallized ligand. The molecular 
structures of the synthesized compounds were built and 
optimized with MOE package (2012.10) with the MMFF94x 
forcefield as implemented in this software. These compounds 
were docked into the homology model of rat intestinal 
glucosidase developed previously by this group and to human 
glucosidase active sites. For each compound, 500 docking runs 
were performed. The following genetic algorithm parameters 
were used: population size = 100; selected pressure = 1.1; 
number of operations = 1000; number of islands = 5; niche size = 
2; migrate = 10; mutate = 95; crossover = 95. Each conformation 
was ranked according to its goldscore scoring function. The top 
solutions (the ones with the highest goldscore) were visually 
inspected and critically evaluated and, for each inhibitor, the 
highest scoring conformation was chosen as the actual binding 
conformation (Figure 3).  
2.4. Homology modelling of the Rat intestinal 
glucosidase:  
To investigate the inhibitory activity of the synthesized 
compounds against rat intestinal glucosidase, a homology 
modeling of α-glucosidase from Rattus norvegicus was carried 
out to predict its 3D-structure (the 3D structure has never been 
resolved experimentally). The amino acid sequence of α-
glucosidase from Rattus norvegicus comprises 953 amino acid 
residues and was retrieved from the UniProt protein resource data 
bank (http://www.uniprot.org/), under the access code Q6P7A9. 
Using the Molecular Operating Environment program (MOE) 
version 2012.10 (http://www.chemcomp.com/software) we 
searched for proper structural templates on the PDB database of 
protein structures and sequences and aligned the results obtained 
with the MOE-Align feature. MOE-Align implement a modified 
version of the alignment methodology originally introduced by 
Needleman and Wunsch. All the default settings in the MOE-
Align panel were used for the sequence alignment. Our search 
identified the Homo sapiens intestinal maltase-glucoamylase (in 
complex with O-sulfonated kotalanol) crystallographic structure 
(PDB code 3L4U, 1.90 Å resolution)[21] sharing 45.7% of 
sequence identity (calculated with BLAST) with α-glucosidase 
enzyme from Rattus norvegicus as the most suitable template. 
The catalytic site is highly conserved in both structures. The 
crystallographic structure and the homology model were 
superposed with MOE software and the RMSD values obtained 
were 1.04 Å for the Rattus norvegicus homology model. The 3D 
homology models were built with Molecular Operating 
Environment (MOE) software using only a single template and a 
set of 10 intermediate models were generated and refined with 
Amber99 forcefield, resulting in the corresponding homology 
model. The stereochemical quality of the enzyme backbone and 
side chains was validated by Ramachandran plots. To validate the 
model we first docked kotanalol into the structure’s active site 
and compared the final docked complexes with the 
crystallographic structure obtained by Sim et al.[21] We 
confirmed that kotanalol was placed in an identical position to 
that adopted in the crystallographic structure (PDB ID: 3L4U) 
having similar active site residue interactions.  
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Figure 3. – Docking poses of DNJ and compound 5 inside human α-glucosidase active site. 
Besides that, acarbose (a known α-glucosidase inhibitor widely 
used in the treatment of diabetes type 2) was also docked into the 
homology model active site, and was correctly placed. 
2.5. Synthesis of Pyrrolidine Iminocyclitol Inhibitors 
Synthesis of (3R)-1-benzyl-3-hydroxypyrrolidine-2,5-dione 
(1): (3R)-1-benzyl-3-pyrrolidine-2,5-dione 1 was synthesized 
according to the thermal condensation method [22a,23]. The 
enantioselectivity was determined by chiral HPLC (column AD-
H, (60:40) n-hexane:ethanol, 1 mL/min) tR= 15.8 min, 98% ee.  
Synthesis of (3S)-1-benzyl-3-hydroxypyrrolidine-2,5-dione 
(1’): (3S)-1-benzyl-3-hydroxypyrrolidine-2,5-dione 1’ was 
synthesized according to the thermal condensation 
method[22a,23]. The enantioselectivity was determined by chiral 
HPLC (AD-H, (60:40) n-hexane:ethanol, 1 mL/min: tR= 20.6 
min, 100% ee.   
Synthesis of (3R)-1-benzyl-3-acetatepyrrolidine-2,5-dione 
(2): (3R)-1-benzyl-3-hydroxypyrrolidine-2,5-dione 1 (300 mg, 
1.5 mmol) was dissolved in pyridine (0.78 mL) and acetic 
anhydride (1.23 mL) was then added. The solution was stirred for 
23h at rt. The solvents were removed in vacuo, and the crude 
product was purified by silica gel column chromatography [(2:1) 
to (1:1) Hex:EtOAc)] to give the title compound as a light brown 
solid (0.19 g, 52%).  
1H NMR (CDCl3, 400 MHz) δ: 2.14 (s, 3H, CH3) ppm, 2.64 
(dd, J 4, 20 Hz, 1H, CH2CO), 3.13 (dd, J 8, 20 Hz, 1H, CH2CO), 
4.6 (d, J 20 Hz, 1H, ABX system, CH2Ph), 4.7(d, J 12,1H, ABX 
system, CH2Ph), 5.42 (dd, J 8, 12 Hz, 1H, CHOAc), 7.33 (m, 5H, 
Ph). 13C NMR (100.6 MHz, CDCl3): δ = 20.5 ppm, 35.7, 42.6, 
67.5, 128.1, 128.7, 128.9, 135.1, 169.8, 172.9, 173.2. [α]28D = 
+20.6 (c 1.45, CHCl3). {[α]20D = +39 (1%, w/v MeOH)} [24].
Synthesis of (3S)-1-benzyl-3-acetatepyrrolidine-2,5-dione 
(2’): (3S)-1-benzyl-3-acetatepyrrolidine-2,5-dione 2’ was 
synthesized according the procedure described previously, the 
title compound was obtained as a brown solid (0.29 g, 78%).    
1H NMR (400 MHz, CDCl3): δ  2.14 (s, 3H, CH3) ppm, 2.64 
(dd, J=4, 16 Hz, 1H, CH2CO), 3.14 (dd, J 8, 20 Hz, 1H, CH2CO), 
4.65 (d, J 16 Hz, 1H, ABX system, CH2Ph), 4.70 (d, J 16 Hz, 1H, 
ABX system, CH2Ph), 5.25 (dd, J 4, 8 Hz, 1H, CHOAc), 7.34 
(m, 5H, Ph). 13C NMR (100.6 MHz, CDCl3): δ 20.5 ppm, 35.7, 
42.7, 67.5, 128.2, 128.7, 128.9, 135.2, 169.8, 172.9, 173.2. [α]28D 
= -21.5 (c 1.14, CHCl3). {[α]20D = -40.6 (1%, w/v MeOH)} [22].
Synthesis of (3R)-1-benzyl-3-hydroxypyrrolidine (3): (3R)-
1-benzyl-3-hydroxypyrrolidine 3 was synthesized according to 
  
the method described by Zheng et al.[22a] [α]29D = +56.3 (c
0.045, CHCl3). 
Synthesis of (3S)-1-benzyl-3-hydroxypyrrolidine (3’): (3S)-
1-benzyl-3-hydroxypyrrolidine-2,5 3’ was synthesized according 
to the method described by Zheng et al.[22a] [α]29D = -3.14 (c
1.08, CHCl3). {[α]25D = -3.145 (c 1.2, CHCl3)}[22a]
Synthesis of (3R)-1-benzyl-3-acetatepyrrolidine (4): (3R)-1-
benzyl-3-acetatepyrrolidine 4 was synthesized according to the 
method described for compound 2, the title compound was 
obtained as a brown solid (0.14 g, 63%).    
1H NMR (400 MHz, CDCl3): δ 1.85 (m, 1H, CH2) ppm, 2.03 
(s, 3H, CH3), 2.25 (m,1H, CH2), 2.46 (m, 1H, CH2), 2.66 (m, 1H, 
CH2), 2.8 (m, 2H, CH2), 3.60 (d, J 12 Hz, 1H, ABX system, 
CH2Ph), 3.7(d, J 12 Hz, 1H, ABX system, CH2Ph), 5.17 (m, 1H, 
CHOAc), 7.28 (m, 5H, Ph); 13C NMR (100.6 MHz, CDCl3): δ
21.0 ppm, 31.6, 52.5, 59.7, 60.1, 74.1, 127.6, 128.7, 129.4, 138.6, 
171.0. [α]28D = +5.01 (c 3.77, CHCl3). {[α]D = +22.0 (c 5, 
MeOH)}[25]  
Synthesis of (3S)-1-benzyl-3-acetatepyrrolidine (4’): (3S)-
1-benzyl-3-acetatepyrrolidine 4’ was synthesized according to 
the method described for compound 2, the title compound was 
obtained as a brown solid (0.11 g, 49%).    
1H NMR (400 MHz, CDCl3): δ 1.86 (m, 1H, CH2) ppm, 2.04 
(s, 3H, CH3), 2.27 (m,1H, CH2), 2.40 (m, 1H, CH2, 2.66 (m, 1H, 
CH2), 2.78 (m, 2H, CHH), 3.60 (d, J 12 Hz, 1H, ABX system, 
CH2Ph), 3.69 (d, J 16 Hz, 1H, ABX system, CH2Ph), 5.18 (m, 
1H, CHOAc), 7.29 (m, 5H, Ph); 13C NMR (100.6 MHz, CDCl3):
δ 21.3 ppm, 31.9, 52.7, 59.9, 60.2, 74.1, 127.6, 128.3, 128.9, 
138.5, 171.0. [α]28D = -19 (c 2.4, CHCl3). {[α]20D = -23.0 (c 1, 
MeOH)}[26] 
Synthesis of (3R,4R)-1-benzyl-3,4-dihydroxypyrrolidine 
(5): (3R,4R)-1-benzyl-3-dihydroxypyrrolidine 5 was synthesized 
according to the method of Nagel [23]. [α]20D = -30.5 (c 4.23, 
MeOH). 
Synthesis of (3S,4S)-1-benzyl-3,4-dihydroxypyrrolidine 
(5’): (3S,4S)-1-benzyl-3-dihydroxypyrrolidine 5’ was 
synthesized according to the method of Nagel [23]. [α]20D = +40 
(c 3.7, MeOH) [[α]20D = +32.4 (c 4.2, MeOH)] [23a]. 
Synthesis of (3R,4R)-1-benzyl-3,4-
bis(benzyloxy)pyrrolidine (6) 
NaH (0.828 g of 60% dispersion in mineral oil, 21 mmol) was 
added to a suspension of (3R,4R)-1-benzyl-3,4-pyrrolidinediol 5
(1 g, 5.2 mmol) in anhydrous DMF (2 mL) at room temperature. 
The suspension was stirred for 3min then cooled in an ice bath. 
Benzyl bromide (1.85 mL, 16 mmol) was added dropwise over a 
5-min period, and after 1min the ice bath was removed. The 
reaction mixture was stirred overnight, and then 1 mL of MeOH 
was added slowly to react with the excess of the NaH. DMF was 
removed under reduced pressure at 55ºC. The residue was 
dissolved in CH2Cl2 (25 mL) and washed with water and brine, 
dried (MgSO4), filtered, and evaporated to give the crude product 
6 as a yellow oil which was purified by silica gel column 
chromatography [hexane, to (9:1) hexane:EtOAc to EtOAc] (1.16 
g, 60%, as a colorless oil). 
1H NMR (400 MHz, CDCl3): δ 2.74 ppm (dd, J 4, 8 Hz, 2H, 
CH2), 2.99 (dd, J 4, 12 Hz, 2H, CH2), 3.66 (d, J 12 Hz, 1H, ABX 
system, CH2), 3.73(d, J 12 Hz, 1H, ABX system, CH2), 4.16 (d, 
2H, 2xCH), 4.57 (q, 4H, 2x CH2Ph), 7.37 (m, 15H, Ph). 13C 
NMR (100MHz, CDCl3): δ 58.5 ppm, 60.4, 71.5, 83.7, 127.1, 
127.7, 127.9, 128.3, 128.4, 129.0, 138.2, 138.4.  [α]D28 = -28.6 (c
1.13, CHCl3). MS (ESI-TOF) 374.22 (M+1).   
(3R,4R)-pyrrolidine-3,4-diol (7):  
A dry 5mL round-bottomed flask containing a magnetic 
stirring bar was charged with (3R,4R)-1-benzyl-3,4-
dihydroxypyrrolidine diol 5 (0.45 g, 2.3 mmol, EtOH (15 mL) 
and Pd(0)En cat 3NP (1 g, 0.4 mmol Pd/g). A balloon filled with 
hydrogen was attached to the flask, the mixture was warmed to 
50ºC and stirred for 26 h. It was then allowed to cool to room 
temperature, filtered and washed with CH2Cl2 (3mL), and the 
solvent was removed in vacuo giving 7 (0.24 g, 100%) as a white 
solid.  
1H NMR (400 MHz, D2O): δ 3.36 ppm (d, J 12Hz, CHH, 2H), 
3.6 (d, J 12Hz, CHH, 2H), 4.41 (s, 2H, CHO, 2H). 13C NMR 
(D2O, 100MHz): δ 49.2 ppm, 72.7.  
1-Benzyl pyrrolidine (8):  
To a round bottom flask (100 mL) with a magnetic stir bar 
was added pyrrolidine (1g, 14 mmol), THF (10 mL) and
triethylamine (1.94 mL, 14 mmol). The mixture was cooled to 
0ºC and benzyl bromide (1.67 mL, 21 mmol) was added drop 
wise over 15 min. The mixture was stirred until all the substrate 
was consumed. The solids were filtered and the filtrate was 
concentrated in vacuo. The crude product 8 was dissolved in 
CH2Cl2 (2 mL) and washed with water (2 mL). The organic phase 
was dried with MgSO4, filtered and concentrated giving 8 (1.0 g, 
46%) as yellow oil [27].  
1H NMR (400 MHz, CDCl3): δ 1.81 ppm (m, 4H, CH2), 2.53 
(m, 4H, CH2), 3.64 (s, 2H, CH2), 7.31 (m, 5H, Ph). 13C NMR 
(100 MHz, CDCl3): δ 23.5 ppm, 54.3, 60.9, 126.9, 128.3, 129.0, 
139.5.  
3. Results and Discussion 
3.1. Chemistry  
In the case of the synthesis of 1-benzyl-3-hydroxypyrrolidine 
derivatives [22] D- or L-malic acid were used as substrates 
(Scheme 1). In the case of compounds 1 and 1’, two methods 
were used, in the first method only 89% ee was obtained (1st step 
formation of hydroxyamide; 2nd step cyclization to form the 
malimide). The first method was originally reported by Joullié et 
al.[22b] It seems that the second step which involved heating at 
high temperature without solvent gave some racemization. In the 
second method using a direct thermally induced condensation 
between the malic acid and the amine, in xylene, an enantiopurity 
of 99%ee was obtained for the product. For the synthesis of 3 and 
3’ the method described by Zheng et al.,[22a] was used and the 
yields were approximately 50%. The acetylation of 1, 1’, 3, and 
3’ with pyridine and acetic anhydride formed the products 2, 2’, 
4 and 4’, respectively [7]. 
The non-hydroxylated 1-benzyl pyrrolidine 8 was synthesized 
by alkylation of pyrrolidine using triethylamine and benzyl 
bromide, furnishing the product in a yield of 46% without any 
purification (Scheme 2). This compound was used as a reference. 
(3R,4R)-1-Benzyl-3,4-pyrrolidinediol 5 and the respective 
enantiomer 5’ were synthetized using the method of Nagel.23 The 
dibenzylated derivative 6 was obtained by protecting the 
hydroxyl groups of 5 using NaH in DMF and benzylbromide, the 
yield was good.  
(3R,4R)-Pyrrolidine-3,4-diol 7 (Scheme 3) was synthetized 
using supported palladium (0) - Pd-EnCat - and this was used in 
order to avoid leaching of the metal into the product, which is a 
problem with these systems [28].
  
Scheme 1. Reaction conditions: (a)(i) BnNH2, MeOH/H2O, 
170ºC; (ii) 160ºC (b) BnNH2, Xylene, 170ºC (c) LiAlH4, THF, 
NaOH (20%) (d) py, Ac2O, rt 
Scheme 2. Reaction conditions: NEt3, THF, BnBr, 0oC to rt. 
Scheme 3. Reaction Conditions: (a) Pd(0)EnCat, EtOH, 
H2;(b) NaH, DMF, BnBr. 
3.2. Biological screening and Toxicological studies 
The synthetized compounds were assayed for the inhibition of 
rat intestine α-glucosidase using inhibitor concentrations between 
0 and 46 mM, with the exception of compound 8 which was used 
at concentrations of between 0 and 92 mM. DNJ was used as the 
positive control. The IC50 for DNJ inhibition of rat α-glucosidase 
was found to be in the nM range (IC50=0.167 ± 0.016 μM) (Fig. 
3(A)) and consistent with other reports [29]. Table 1 shows the 
IC50 of the studied iminosugars, determined by the inhibition 
curves (Fig. 4 (A)). Based on the results shown in the table 1, all 
the compounds containing a 2,5- carbonyl group (1, 1’, 2, 2’) 
failed to evoke any inhibition; on the contrary all the examples 
lacking this group have shown inhibition in the concentration 
range 0.01 – 72 mM. As expected 1-benzylpyrrolidine 8, showed 
very poor inhibitory action (with an IC50 of 72 mM), suggesting 
the requirement of hydroxyl groups in the pyrrolidine ring. Both 
enantiomers 2 and 2’, have an acetoxyl group in the 3-position 
of the pyrrolidine ring. In this case, however, it was not possible 
to determine an exact IC50 value; instead a value in the range of 
10-20 mM was inferred. The main reason for this result was that 
probably the acetylated compounds suffered partial hydrolysis 
during the inhibition period leading to a mixture of acetylated 
and deacetylated products. In the case of the monohydroxylated 
compounds 3 and 3’, the IC50 were 4.6±0.1 and 4.2±0.3 mM, 
respectively. These compounds are better inhibitors than the 
respective acetylated compounds (2 and 2’), perhaps as a result 
of better interactions with the active site of the enzyme. The 
same was the case for compound 6, with a lower IC50 value 
compared to that of compound 5. Another problem with 
compound 6 was its poor solubility in the assay solution hence 
deviations in the solution concentration might occur. In the case 
of the enantiomers 5 and 5’, the IC50 values were 2.97±0.046 and 
5.82±0.034 mM, respectively; Interestingly 5 is more active than 
5’. In an attempt to achieve better inhibition we decided to 
synthetize compound 7, based on the modification of the 
structure of enantiomer 5, making it more polar, with a free NH 
group for interaction by hydrogen bonding, with the active site of 
the enzyme. Unfortunately, the IC50 values increased slightly to 
4.07±0.042 mM. On comparing the monohydroxyl with the 
dihydroxyl compound series, the inhibition is quite similar. 
Based on these results, our best inhibitor was compound 5.  
In order to understand the molecular interactions between the 
inhibitors and the enzyme, we carried out some kinetic studies 
basically to determine the type of inhibition and the (KI) value 
Figure 4 and Table 1.            
Table 1: The concentration of iminosugar giving 50% 
inhibition of α-glucosidase from rat intestine mucosa. 
Inhibitor IC50 (mM) 
DNJ 1.67 x 10-4±0.163x10-4
1 NI 
1’ NI 
2 NI 
2’ NI 
3 4.6 ±0.1 
3’ 4.2±0.3 
4 10-20 
4’ 10-20 
5 2.97±0.046 (KI= 1.18 mM) 
5’ 5.82±0.034 (KI= 0.27±0.25 mM) 
0.01±0.015 
6 7.94  
7 4.07±0.042(KI= 0.44±0.164 mM) 
8 72.0±0.3 
NI: no inhibition 
Only three compounds were selected, 5, 5’ and 7, which were 
the most promising inhibitors. On the basis of the kinetic results, 
all the compounds showed a mixed type of inhibition (Figure 4 
(B) and (C)). Based on the Dixon plot, the mechanism of 
inhibition observed is predominately a mixed competitive type. 
The KI values that were determined were different from the 
respective IC50 values, again indicating competitive inhibition.  
  
Despite the fact that these compounds were moderate α-
glucosidase inhibitors, it still was considered of interest to 
evaluate their toxicological proprieties, particularly as they could 
be used to address other therapeutic targets. The methods used 
were (i) BRIN-BD11 cell viability assay and (ii) artemia Salina 
toxicity assay. In the case of the first method used, Figure 5(A), it 
was observed that compounds 5, 5’ and 7 had low toxicity, 
compound 5 is the most toxic affecting the cellular viability in 
concentration above 12.5 mM and compound 5’ affected the 
cellular viability for concentrations above 25 mM whereas 7 did 
not affect the cellular viability in the range of concentrations 
studied, up to 50 mM. It is noteworthy that these concentration 
values are 4 and 10 times higher than the IC50 of compounds 5/5’
and 7, respectively. In the case of the tests with artemia salina
only the enantiomers 5 and 5’ were evaluated. The results 
obtained show that the LC50 values were 15.53 and 38.56 mM, 
respectively (Figure 5(B)). For both compounds the LC50 is 5 
times higher than the IC50. These results are in agreement with 
the cellular viability test and show that 5’ is less toxic than 5. All 
together, these results suggest that, although moderate inhibitors 
of mammalian α-glucosidase, these compounds might have some 
potential as pharmacological agents for other therapeutic targets. 
In addition, enantiomers 5 and 5’ are more toxic than compound 
7, suggesting that benzylated pyrrolidine are more deleterious 
than debenzylated ones.    
3.3.  Molecular Modeling Studies  
In order to rationalize the experimental inhibitory activity for 
the compounds with different types of substitution in positions 2-
5, the compounds were docked into the two enzymes active site. 
All the compounds were protonated when docked at the α-
glucosidase active site. The results obtained for both enzymes 
were very similar, thus for simplicity, only the docking results 
using human α-glucosidase will be discussed. 
As stated in our previous paper, the docking results show that 
all the tested compounds occupy the same region of the binding 
pocket as the amino group and the corresponding cyclohexenyl 
ring of acarbose. The obtained docking poses show all the 
compounds lying inside the binding cavity and interacting with 
the most important residues, notably, Asp203, Asp542, Asp443, 
Asp327 Arg526 and His600. We also docked DNJ into the α-
glucosidase active site and this showed that the most active 
compounds show a very similar pose when compared with the 
ones obtained for DNJ (Figure 3). 
Compound 5, the most potent compound in the series, is 
predicted to form an H-bond between the pyrrolidine nitrogen 
and Asp443 (1.5 Å), as well having interactions between the 
oxygen atoms from the free hydroxyl groups, with Asp327, 
Asp542 and His600 (catalytic site) stabilizing the enzyme ligand 
complex, in a similar fashion to acarbose and DNJ. A very 
similar pose is observed for compound 7, however, contrary to 
the former, this compound cannot establish interactions with 
Asp203 due to lack of the N-benzyl group. Compounds 3, 3’, 6
and 8 show an inverted pose inside the binding pocket compared 
with compounds 5 and 7. However, it was shown that they can 
establish key interactions with Asp203, Arg526 and Asp542. 
When we compare, for example compounds 5 and 3 (differing in 
the mono and dihydroxypyrrolidine substitution at positions 3 
and 4) we observed an opposed pose inside the binding cavity 
bearing testimony to the importance of disubstitution for 
stabilizing interactions that can improve inhibitory activity. 
Compounds 1, 1’, 2 and 2’ showed a rotated pose (~90º) inside 
the binding pocket when compared with compound 5. Despite the 
fact, that these compounds occupy the same region as the active 
ones, their lack of activity might be due to the fact that they have 
carbonylic oxygen H-bond acceptors at positions 2 and 5, 
apparently forcing them to rotate and lose the important H-
bonding interaction with Asp542.  
4. Conclusions 
Compounds with carbonyl groups in the 2,5-positions of the 
pyrrolidine ring did not show any α-glucosidase inhibition. 
Compounds with protected hydroxyl groups and without this 
group were shown to be poor inhibitors.  
On comparing 3-hydroxylpyrrolidine with (3,4)-
dihydroxylpyrrolidine, analogous IC50 values were observed. 
However, compound 5, a (3R,4R)-dihydroxypyrrolidine, was the 
best inhibitor with a IC50 value of 2.97±0.046 mM. Compound 5
was more potent than its respective enantiomer. 
Kinetic studies on compounds 5, 5’ and 7 revealed a 
mechanism of inhibition predominately of the mixed competitive 
type. Toxicological evaluation has shown that the compounds 
studied have, in general, low toxicity, only presenting deleterious 
effects for concentrations that are 4 to 10 times higher than the 
IC50. Finally, the N-benzylated compounds are more toxic than 
the debenzylated compound 7.   
 Our docking studies suggest that a rotation of ~90º of 
some compounds inside the binding pocket is responsible for the 
complete loss of inhibitory activity.  
We are currently looking at the synthesis of libraries of novel 
sugar-pyrrolidine-diols for glucosidase inhibition.
  
Figure 4 - (A) Inhibitory effects of compounds DNJ (), 3 (), 3’ (), 5 (), 5’ (), 6 () and 7 () against rat α-glucosidase activity, using p-
nitrophenol-α-D-glucopyranoside as a substrate. Values are expressed as the mean±sd (obtained in two independent experiments performed in quintuplicate). 
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DNJ served as positive control. (B) Michaelis-Menten Plot and Dixon Plot for compound 5 in the presence of several concentrations for determination of KI. (C). 
Michaelis-Menten Plot and Dixon Plot for compound 7 in the presence of several concentrations for determination of KI. The values are expressed as mean±sd (5 
replicates).  
Figure 5. (A) Viability of BRIN BD-11 cells with different concentrations of compounds 5, 5’ and 7. Batches of cells without inhibitors (control) and with 1% 
SDS, a cell membrane disrupter, were used as negative and positive control, respectively. *indicates statistical significance relative to controls (p<0.05). (B) 
Mortality (%) of artemia salina vs log[iminosugar 5 or 5’] – dose-response curve.        
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• The synthesis of a library of 13 chiral pyrrolidine 
derivatives. 
•  Enzyme kinetics implied a mixed inhibition mode, 
corroborating our molecular docking studies.  
• Toxicological studies showed that they were non-
toxic. 
• Molecular docking studies indicated the mechanism 
of competitive inhibition.  
